Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ZG006 versus investigator's choice chemotherapy in relapsed small cell lung cancer
CTR20253783Phase 3Active
- Sponsor
- Zelgen
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alveltamig in small cell lung cancer (SCLC) (2 arms), sponsored by Zelgen. Primary endpoint: Overall survival. Started Dec 2025; status: active.
02
Drugs
alveltamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20253783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253783.